Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · January 28, 2016

CDX2 as a Prognostic Biomarker in Stage II and III Colon Cancer

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

The New England Journal of Medicine
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
N. Engl. J. Med 2016 Jan 21;374(3)211-222, P Dalerba, D Sahoo, S Paik, X Guo, G Yothers, N Song, N Wilcox-Fogel, E Forgó, PS Rajendran, SP Miranda, S Hisamori, J Hutchison, T Kalisky, D Qian, N Wolmark, GA Fisher, M van de Rijn, MF Clarke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated